Company / Operating Cash Flow
ImmunityBio, Inc. Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$304.9M
FY2025
5-year range
-$391.2M / -$152.1M
FY2021-FY2025
Trend
+22.1%
vs FY2024
Sector context
#194 of 216
Health Care
What the data says
Among 216 Health Care companies, ImmunityBio, Inc. is in the bottom 10% for operating cash flow. Operating Cash Flow returned to growth in FY2025 after 3 years of decline, reaching -$305M.
Based on SEC 10-K filings.
-$305M in FY2025.
Improved from -$367M to -$305M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 10% in Health CareTop 90% of 216This company -$304.9M Sector average $659.0M
▼
-146.3% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow increased 22.1% year-over-year.
- Ranks #194 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2016.
- Lowest operating cash flow in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -7.50 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$304.9M | +22.1% |
| FY2024 | -$391.2M | -6.7% |
| FY2023 | -$366.8M | -8.7% |
| FY2022 | -$337.5M | -121.9% |
| FY2021 | -$152.1M | +11.4% |
| FY2020 | -$171.7M | -12.9% |
| FY2019 | -$152.1M | -294.1% |
| FY2018 | -$38.6M | -52.5% |
| FY2017 | -$25.3M | -367.1% |
| FY2016 | -$5.4M | +78.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026